Ultragenyx Corp - Multiplikator forward rega marang pendapatan RARE

Lambang korporat lan logo Ultragenyx Pharma (RARE)

Ultragenyx Pharmaceutical is developing a broad portfolio of gene and cell therapies to combat orphan diseases while minimizing patent risks. By analyzing the business's forward P/S, where this metric equals 2.20, one can assess market expectations. Stable management with an impeccable reputation systematically secures approvals for new drugs. Innovations based on mRNA and vector technologies provide patients with access to therapies for the rarest mutations.

RARE ultragenyx.com: Rega mangsa ngarep marang pendapatan ing interval 04.07.2022 - 17.11.2026

Rincian metrik lan analitis perusahaan ultragenyx.com (RARE)

Ringkesan analisis perusahaan:RARE (Ultragenyx Corp)
Sampel barang Ultragenyx Pharmaceutical

High cryogenic logistics costs for Ultragenyx Pharmaceutical (RARE) gene therapies directly impact margins, making the expected P/S ratio a key indicator of market confidence in future sales. This metric correlates current market capitalization with projected revenue, demonstrating investors' willingness to pay a premium for growth potential; its increase confirms market optimism, while a decline indicates an asset overvaluation.

Pesaing Ultragenyx Pharmaceutical (RARE)

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|Multiplikator Forward P/S Beam Therapeutics Inc.|Rasio rega marang prakiraan pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Kapitalisasi marang prakiraan pendapatan|10x Genomics Inc - Multiplikator forward rega marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rega mangsa ngarep marang pendapatan|Stoke Corp - Multiplikator Forward P/S|BLFS (BioLife) - Kapitalisasi marang prakiraan pendapatan|wavelifesciences.com (WVE) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|SION (Sionna Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Prime Medicine Corp (PRME)|Multiplikator Forward P/S TSHA|Multiplikator Forward P/S uniQure N.V. (QURE)|Rasio rega marang prakiraan pendapatan MeiraGTx Holdings plc MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.